References
- Hsu S M, Raine L, Fanger H. Use of avidin-biotin-peroxi-dase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577–80
- Bast R C., Klug T L, Schaetzl E, Lavin P, Niloff J M, Greber T F, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19–9, and carcinoembryonic antigen. Am J Obstet Gynecol 1984; 149: 553–9
- Kuzuya K, Nozaki M, Chihara T. Evaluation of CA 125 as a circulating tumor marker for ovarian cancer. Acta Obstet Gynaecol Jpn 1986; 38: 949–57
- Pittaway D E, Fayez J A. The use of CA 125 in the diagnosis and management of endometriosis. Fertil Steril 1986; 46: 790–5
- Nozawa S, Aoki D, Yajima M, Tsukazaki K, Kobayashi T, Kimura E, et al. CA 54/61 as a marker for epithelial ovarian cancer. Cancer Res 1992; 52: 1205–9
- Kato H, Morioka H, Tsutsui H, Aramaki S, Torigoe T. Value of tumor-antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 1982; 50: 1294–6
- Kato H, Morioka H, Aramaki S, Tamai K, Torigoe T. Prognostic significance of the tumor antigen TA-4 in squamous cell carcinoma of the uterine cervix. Am J Obstet Gynecol 1983; 145: 350–4
- Senekjian E K, Young J M, Weiser P A, Spencer C E, Magic S E, Herbst A L. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol 1987; 157: 433–9
- Kimura T, Inoue M, Miyake A, Tanizawa O, Oka Y, Amem-Iya K, et al. The use of serum TA-4 in monitoring patients with malignant transformation of ovarian mature cystic teratoma. Cancer 1989; 64: 480–3
- Miyazaki K, Tokunaga T, Katabuchi H, Ohba T, Tashiro H, Okamura H. Clinical usefulness of serum squamous cell carcinoma antigen for early detection of squamous cell carcinoma arising in mature cystic teratoma of the ovary. Obstet Gynecol 1991; 78: 562–6